Thiopurine therapy is used as a standard of care in inflammatory bowel disease (IBD), but it might cause fatal myelosuppressive adverse events that require hospitalization. To reduce the risk of myelosuppression hospitalizations, a systematic clinical assessment of patients while on thiopurine therapy is needed. While racial disparities in IBD treatment and management has been well-documented in the US, whether these racial disparities have caused high risk of myelosuppression hospitalizations in minority population is still unknown.